Recombinant Goat Pregnancy-associated glycoprotein 62 (PAG62)

What is the molecular characterization of Pregnancy-associated Glycoprotein in goats?

Pregnancy-Associated Glycoprotein (PAG) is secreted by the placenta and produced in mononucleate and binucleate trophoblast cells in goats. The molecular weight of PAG from Etawa crossbred goats has been identified as 55.85 kDa . PAGs are N-glycosylated proteins, and their carbohydrate content can reach approximately 9.66% in some species, with deglycosylation using PNGase F typically reducing molecular weight by about 4.68 kDa .

PAGs demonstrate pregnancy stage-dependent glycosylation patterns. During early implantation (day 16 post-conception), native mature G-forms of pPAG proteins of 43 kDa can be deglycosylated to faster-migrating D-forms of approximately 39.6 and 36.9 kDa. On day 17 post-conception, 65-68 kDa G-forms can be reduced to three D-forms: 50.6, 58.7, and 63.5 kDa . This indicates significant N-linked carbohydrate content during early placental development.

What biological functions do PAGs serve in goat pregnancy?

PAGs serve multiple critical functions during pregnancy:

• They induce the release of granulocyte chemotactic protein-2 (GCP-2), an alpha chemokine whose synthesis is induced by interferon-tau in early pregnancy

• They exhibit luteotropic roles by inducing the release of prostaglandin E2 and progesterone from luteal cells

• They participate in the remodeling of fetal membranes throughout pregnancy

• They function as reliable indicators of fetal well-being, as their production depends on healthy trophoblastic tissue

• PAG2 specifically has been shown to be similar to LH, forming bonds with CL receptors and demonstrating immunological kinship

How do PAG concentrations change throughout goat pregnancy?

PAG concentrations show a clear progression throughout pregnancy. In non-pregnant Etawa crossbred goats, baseline PAG levels average 1.83±2.98 units. During pregnancy, PAG concentrations increase to approximately 3.79±2.72 units at three months and 4.36±2.63 units at four months of gestation .

PAGs become detectable in maternal circulation through heterologous RIA or ELISA techniques as early as 21 days after breeding, though day 24 post-AI is recommended for farm conditions . They also become detectable in milk from approximately day 32 post-conception, with day 26 post-mating reported as the first time-point for significantly higher milk PAG concentrations and day 37 post-mating suggested as the optimal time point for pregnancy detection in goats using milk PAG assays .

What are the optimal experimental designs for evaluating recombinant PAG functionality?

When designing experiments to evaluate recombinant PAG62 functionality, several critical considerations should be addressed:

Sample size and experimental design:

• Increasing the number of test subjects (goats) improves precision and reproducibility more efficiently than increasing replicates within a single subject

• For statistical significance using ANOVA with 80% power:

  • With a single test line: 6 subjects per treatment group to detect a difference of 135 days, and 9 subjects to detect a difference of 100 days

  • With 10 test lines: 1-2 subjects per line per treatment group is sufficient for detecting differences of 100-135 days

Control considerations:

• Include sufficient untreated controls (at least 6 controls)

• In plate-based assays, avoid edge effects by not using outermost wells or include equal numbers of controls at edges and center

• Position controls effectively to detect potential edge effects

Technical replicates:

• Minimum 3 technical replicates for simple dose-response experiments

• 6 or more replicates when measuring small differences (less than 0.2) or time-dependent values

• More replicates are necessary for precisely assessing time-dependent values, especially for short time intervals or slowly growing cell lines

Data analysis considerations:

• Power for Cox regression is slightly smaller than ANOVA for very small experiments regardless of effect size

• Cox regression may be slightly higher than ANOVA for detecting smaller effect sizes in moderate-to-large experiments

How can CRISPR/Cas9 technology be utilized for studying PAG function or producing recombinant PAG?

CRISPR/Cas9 technology has been successfully applied in goats with high efficiency (9%-70%) and offers several valuable approaches for PAG research :

For creating knockout models to study PAG function:

• Design gRNAs targeting the PAG gene of interest

• Transfect goat fibroblasts with Cas9/gRNA plasmids

• Verify modifications via restriction fragment length polymorphism (RFLP) assay and DNA sequencing

• Use modified fibroblasts for somatic cell nuclear transfer (SCNT)

• Generate live-born goats with targeted mutations (achievable within approximately 5 months)

For creating mammary bioreactor models to produce recombinant PAG:

• Design a homologous plasmid with T2A-PAG sequences

• Knock the PAG sequence into the seventh exon of the goat β-casein (CSN2) gene under the control of the CSN2 promoter

• Microinject a mixture of Cas9 mRNA, sgRNA, and homologous plasmid into donor goat embryos

• Transplant into recipient goats through embryo transfer

• The resulting transgenic goats will express the PAG gene and facilitate protein production through the mammary glands

This approach has been successfully demonstrated with other proteins and could create genetically edited goats that secrete PAG with mammary-specific characteristics, providing a scientific basis for further development of transgenic goat breeds .

What strategies are most effective for site-specific conjugation and labeling of recombinant PAG?

Novel site-specific conjugation methods developed for goat antibodies can be adapted for PAG labeling:

Chemo-enzymatic glycan remodeling approach:

• Identify N-glycosylation sites in PAG through proteomics analysis:

  • Process MS and MS/MS data against the goat sequence database

  • Identify glycopeptides and their glycosylation sites

  • Resolve N-glycosylation heterogeneity

• Enzymatic modification:

  • Use endoglycosidases (like EndoS2) to cleave N-glycans at specific sites

  • EndoS2 treatment shows a downward shift for the heavy chain band on SDS-PAGE gels, consistent with loss of one N-glycan per chain

• Azide activation and click chemistry:

  • Install a reactive azide handle through glycan remodeling

  • Perform click chemistry with strained alkyne partners (like DBCO-mPEG)

  • This creates homogeneous conjugates labeled only on specific domains

Verification methods:

• SDS-PAGE to observe shifts in molecular weight (e.g., PEGylation shifts from ~50 to ~75 kDa)

• Western blotting with specific antibodies

• Mass spectrometry for detailed glycan profiling

This approach ensures site-specific modification without affecting protein function, producing homogeneous conjugates that retain their biological activity. The method is robust and should be applicable to PAG with similar success .

How do PAG concentrations correlate with fetal number and viability in goats?

PAG concentrations provide valuable information about fetal status and can be used to monitor pregnancy health:

Correlation with fetal number:

• PAG levels are significantly higher in twin-bearing goats compared to those carrying a single fetus

• Concentrations are approximately ten times higher in interspecific pregnancies (Spanish ibex embryos transferred to domestic goats) compared to normal intraspecific gestation

Correlation with fetal viability:

• Consecutive PAG measurements can detect trophoblastic activity disorders leading to fetal death

• PAGs are synthesized by mono- and binucleate cells of the trophectoderm, which migrate from fetal to uterine tissue

• This active process requires healthy trophoblastic tissue; if this condition fails, the source of production is missing

Detection methods and timing:

These patterns would be essential to establish when developing and validating recombinant PAG-based diagnostic assays .

What mechanisms underlie the pregnancy stage-dependent N-glycodiversity of PAGs in goats?

The search results reveal significant pregnancy stage-dependent N-glycodiversity of PAG proteins in goats:

• During implantation (days 16-17), the highest level of N-linked carbohydrate content is observed

• Native mature G-forms undergo different patterns of deglycosylation when treated with PNGase F, converting to various D-forms with reduced molecular weights

• This demonstrates post-transcriptional modifications of released native N-glycosylated PAG protein family

Potential mechanisms:

• Differential expression of glycosyltransferases in trophoblast cells at different pregnancy stages

• Changes in the cellular environment affecting post-translational processing

• Expression of different PAG isoforms at different pregnancy stages

The stage-dependent N-glycodiversity of PAG proteins likely plays fundamental roles during implantation and pregnancy maintenance in ungulate species where CG (Chorionic Gonadotropin) has not been identified. The degrees of glycosylation, glyco-diversities, unique oligosaccharide content, and post-translational processing are probably essential for proper placental functioning and appropriate embryo-maternal steroid/gonadotrophin exchange during pregnancy .

Understanding these mechanisms is crucial when designing recombinant PAG expression systems, as the glycosylation pattern affects protein function and should ideally match the pattern observed in the native protein at the pregnancy stage of interest.

How can recombinant PAG be effectively produced in mammary gland bioreactors?

The development of mammary gland bioreactors represents a promising method for recombinant PAG production:

CRISPR/Cas9-based approach:

• Design the target gene knock-in:

  • Target the seventh exon of the goat β-casein (CSN2) gene

  • Place PAG under control of the CSN2 promoter using T2A peptide sequence

  • Create a homologous plasmid containing the T2A-PAG sequences

• Generate transgenic embryos:

  • Prepare a mixture of Cas9 mRNA, sgRNA, and the homologous plasmid

  • Microinject this mixture into donor goat embryos

  • Transplant injected embryos into recipient goats using embryo transfer technology

• Verify transgenic offspring:

  • Confirm successful gene editing through PCR and sequencing

  • Assess PAG expression in milk during lactation

  • Quantify protein production levels and biological activity

This approach has been successfully demonstrated with the human neutrophil peptide 1 (HNP1) and could be adapted for PAG production. The resulting transgenic goats would express PAG with mammary-specific characteristics, secreting the recombinant protein in milk .

The advantages of this system include:

• Expression in a natural biological system with appropriate post-translational modifications

• Continuous production of the recombinant protein during lactation

• Scalability through breeding additional transgenic animals

• Expression levels controlled by the strong mammary-specific promoter

What challenges exist in standardizing recombinant PAG for pregnancy diagnosis across different goat breeds?

Standardizing recombinant PAG for pregnancy diagnosis across different goat breeds presents several challenges:

Breed consistency:

Pregnancy variables affecting standardization:

• PAG levels are significantly higher in twin-bearing goats than in single-fetus pregnancies

• Concentrations are approximately ten times higher in interspecific pregnancies compared to normal intraspecific gestation

• The stage of pregnancy significantly affects PAG glycosylation patterns and concentrations

Detection method considerations:

• Blood-based tests can detect pregnancy earlier (21-24 days) than milk-based tests (26-32 days)

• Visual PAG-ELISA tests for field use from day 28 still need verification for reliability

• The optimal timing for milk PAG detection appears to be day 37 post-mating

A standardized recombinant PAG-based diagnostic system would need to account for these variables through appropriate calibration and interpretation guidelines to provide reliable results across different breeds, pregnancy types, and stages.

Table 1: PAG Concentration Progression in Etawa Crossbred Goats

Source: Data extracted from

Table 2: PAG Detection Methods Comparison

Source: Synthesized from

Table 3: Statistical Power Requirements for Experimental Design